Scholar Rock: More Than Just An SMA Biotech With Q2 2025 …

1 day ago · Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

CouponFollow Extension

300%
OFF

Scholar Rock Scores $300M For Regulatory Filings & Launch Plans …

3 weeks from now

Oct 9, 2024 · Shares of Scholar Rock soared more than 300% after the biotech’s data release, and the company seized on the opportunity to raise money. Late Tuesday, Scholar Rock …

medcitynews.com

$2
OFF

Scholar Rock Preps Filings After SMA Antibody Clears Trial

3 weeks from now

Oct 8, 2024 · Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug apitegromab clears a phase 3 trial, with filings now expected in Q1 2025.

pharmaphorum.com

$345
OFF

Scholar Rock's SMA Drug Hits Phase 3 Trial Goals; Secures $345M …

3 weeks from now

Nov 12, 2024 · Scholar Rock (SRRK) reported positive Phase 3 SAPPHIRE trial results for apitegromab in Spinal Muscular Atrophy (SMA), achieving its primary endpoint with statistically …

stocktitan.net

FAQs about Scholar Rock: More Than Just An SMA Biotech With Q2 2025 … Coupon?

Does scholar rock have an anti-myostatin inhibitor apitegromab?

Scholar Rock has done well to advance its anti-myostatin inhibitor apitegromab for the treatment of patients with Spinal Muscular Atrophy [SMA]. Especially, when you consider that it was able to submit its BLA of this drug to the FDA for review. ...

Does scholar rock treat muscle atrophy?

Scholar Rock takes a different and perhaps complementary approach to available SMA therapies. Treatments that target SMN prevent further degeneration of motor neurons, but they do not directly affect muscle atrophy, the company said in an investor presentation. ...

How much did Scholar Rock Raise in a stock offering?

On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. ...

What is scholar rock doing with apitegromab?

Scholar Rock is testing apitegromab in combo with GLP-1 agonists in a Phase 2 study, with results due in Q2 2025, and has a second pipeline candidate, SRK-439, for which it hopes to secure an Investigational New Drug ("IND") approval next year. ...

Why is scholar rock funded?

"Scholar Rock is funded to scale up and drive forward our key priorities in 2025, including the commercialization of apitegromab, the EMBRAZE readout, the initiation of clinical development for SRK-439, and growing our pipeline," said Ted Myles, Chief Operating Officer and Chief Financial Officer of Scholar Rock. ...

How much cash did Scholar Rock Raise in 2024?

According to the 10-Q SEC Filing, Scholar Rock had cash, cash equivalents and marketable securities of approximately $139.1 million as of September 30th of 2024. This definitely would not be enough cash to move towards a BLA filing for it, or advance the rest of its pipeline. With that said, the company did raise cash to continue to fund itself. ...